It is not in the best interest of anyone to just simply hand out a check.
Yet, contrary to all expectations, this does not trigger cell death in prostate cancer tumors. So the scientists asked: how do these cancers protect their own integrity, and how can we disrupt that defense mechanism?
In order to answer this question, the researchers worked with mice that had been genetically engineered to develop prostate cancer — specifically, tumors presenting a pair of genetic mutations found in almost half of all individuals with treatment-resistant prostate cancer.
But, to the team's surprise, prostate cancers presenting these mutations also had lower levels of protein synthesis — unlike less aggressive types of cancer, which presented only one mutation.
"I spent 6 months trying to understand if this was actually occurring, because it's not at all what we expected," confesses study co-author Crystal Conn..